Pemetrexed for the maintenance treatment of non-small-cell lung cancer

Appraisal Committee members

The Appraisal Committees are standing advisory committees of NICE. Members are appointed for a 3-year term. A list of the Committee members who took part in the discussions for this appraisal appears below. There are four Appraisal Committees, each with a chair and vice chair. Each Appraisal Committee meets once a month, except in December, when there are no meetings. Each Committee considers its own list of technologies, and ongoing topics are not moved between Committees.

Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.

The minutes of each Appraisal Committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.

Dr Kathryn Abel
Reader and Consultant Psychiatrist/Director of Centre for Women's Mental Health, University of Manchester

Dr David Black
Director of Public Health, Derbyshire County Primary Care Trust

Dr Daniele Bryden
Consultant in Intensive Care Medicine/Anaesthesia Sheffield Teaching Hospitals NHS Trust

Professor Mike Campbell
Statistician, Institute of Primary Care and General Practice, University of Sheffield

David Chandler
Lay member

Mary Cooke
Lecturer School of Nursing, Midwifery and Social Work, University of Manchester

Dr Chris Cooper
GP, St John's Way Medical Centre, London

Professor Peter Crome
Professor of Geriatric Medicine, Bucknall Hospital

Dr Christine Davey
Senior Researcher, North Yorkshire Alliance Research and Development Unit

Richard Devereaux-Phillips
Public Affairs and Reimbursement Manager UK and Ireland, Medtronic

Professor Rachel A Elliott
Lord Trent Professor of Medicines and Health, University of Nottingham

Stephen Greep
Chief Executive of Hull and East Yorkshire Hospitals NHS Trust

Dr Wasim Hanif
Consultant Physician and Honorary Senior Lecturer University Hospital Birmingham

Dr Alan Haycox
Reader in Health Economics, University of Liverpool Management School

Professor Catherine Jackson
Professor of Primary Care Medicine, University of St Andrews

Dr Peter Jackson
Clinical Pharmacologist, University of Sheffield

Professor Henry Marsh
Consultant Neurosurgeon, St George's Hospital

Professor Gary McVeigh (Vice Chair)
Cardiovascular Medicine, Queens University Belfast and Consultant Physician Belfast City Hospital

Dr Eugene Milne
Deputy Medical Director, North East Strategic Health Authority

Dr Neil Myers
GP, Helensburgh, Glasgow

Dr Richard Nakielny
Consultant Radiologist, Sheffield Teaching Hospitals Foundation Trust

Mrs Ruth Oliver-Williams
Head of Nursing/Quality Improvement Lead Surgical Services, Royal Derby Hospital

Dr Katherine Payne
Health Economics Research Fellow, University of Manchester

Dr Danielle Preedy
Lay member

Dr Martin J Price
Head of Outcomes Research, Janssen-Cilag

Dr Peter Selby
Consultant Physician, Central Manchester University Hospitals NHS Foundation Trust

Dr Surinder Sethi
Consultant in Public Health Medicine, North West Specialised Services Commissioning Team

Miles Scott
Chief Executive, Bradford Teaching Hospitals NHS Foundation Trust

John Stevens
Director, Centre for Bayesian Statistics in Health Economics, University of Sheffield

Professor Andrew Stevens (Chair)
Professor of Public Health, University of Birmingham

Dr Matt Stevenson
Technical Director, School of Health and Related Research, University of Sheffield

Professor Paul Trueman
Health Economics Research Group, Brunel University

Dr Judith Wardle
Lay member

NICE project team

Each technology appraisal is assigned to a team consisting of one or more health technology analysts (who act as technical leads for the appraisal), a technical adviser and a project manager.

Raphael Yugi
Technical Lead

Eleanor Donegan
Technical Adviser

Laura Malone and Jeremy Powell
Project Managers

Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group:

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers, or sponsors, were also invited to make written submissions. Professional or specialist and patient or carer groups, and other consultees, had the opportunity to give their expert views. Manufacturers, or sponsors, professional or specialist and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Manufacturer or sponsor:

Professional or specialist and patient or carer groups:

Other consultees:

Commentator organisations (did not provide written evidence and without the right of appeal):

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on Pemetrexed for the maintenance treatment of non-small-cell lung cancer by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

Representatives from the following manufacturer or sponsor attended Committee Meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.